|Bid||36.80 x 800|
|Ask||39.85 x 800|
|Day's Range||37.30 - 38.75|
|52 Week Range||20.29 - 43.23|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2017 - Jun 2, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.64|
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced two recent online publications of preclinical studies showing significant silencing, or knockdown, of the mutated gene most commonly known to lead to onset of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two devastating neurodegenerative diseases. The proof-of-concept studies were conducted by uniQure scientists and utilized the Company’s miQURE™ technology, a proprietary, next-generation gene-silencing platform.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching uniQure N.V. (NASDAQ:QURE) might wantRead More...
UniQure NV said on Friday its gene therapy to treat patients with a blood disorder, hemophilia B, increased the levels of a protein that helps in blood clotting after 12 weeks. The updated data from a mid-stage study showed that all three patients on the therapy, AMT-061, showed increasing and sustained levels of factor IX, which helps stop bleeding through blood clots. Hemophilia B is a genetic disorder where the lack of enough factor IX (FIX) prevents blood from clotting, resulting in severe bleeding.
~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency. “We are very pleased to have successfully administered AMT-061 to the first patient enrolled in the HOPE-B pivotal trial and mark this as a milestone for the field in advancing a potential one-time treatment for patients with hemophilia B,” said Robert Gut, M.D., Ph.D., chief medical officer of uniQure.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. “The FDA’s clearance of our IND for AMT-130 is a significant milestone for Huntington’s disease patients and an important event in the field of gene therapy,” said Matt Kapusta, chief executive officer at uniQure.
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]
If you want to know who really controls uniQure N.V. (NASDAQ:QURE), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established Read More...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated results from its ongoing Phase I/II trial of AMT-060, and provided an update on AMT-061, the Company’s next-generation gene therapy candidate currently in late-stage clinical development for patients with hemophilia B. AMT-060 is a first-generation gene therapy consisting of an AAV5 vector carrying a gene cassette with the wild-type FIX gene. The data on AMT-060 includes up to two and a half years of follow-up from the low-dose cohort and up to two years of follow-up from the second, higher-dose cohort. These clinical data were presented on Sunday, December 2 in a poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, California.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bayer announced Thursday it will cut 12,000 jobs amid a strategic overhaul to focus on its pharmaceuticals, consumer health and crop science businesses.
Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.
uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
uniQure (QURE) delivered earnings and revenue surprises of 6.35% and -6.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Amsterdam-based company said it had a loss of 59 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...